1. N-myristoyltransferase inhibition is synthetic lethal in MYC-deregulated cancers
- Author
-
Gregor A. Lueg, Bartlett E, Martin Janz, Probir Chakravarty, Dinis Pedro Calado, Miriam Llorian-Sopena, Mathew J. Garnett, Carr R, Monica Faronato, Andrew Simon Bell, Roberto Solari, Andrii Gorelik, Edward W. Tate, J.A. Hutton, Francesco Falciani, Eva Caamaño-Gutiérrez, Brzezicha B, and Goya Grocin A
- Subjects
Programmed cell death ,Chemistry ,medicine.medical_treatment ,Cancer cell ,medicine ,Cancer research ,Protein biosynthesis ,Cancer ,Protein myristoylation ,Synthetic lethality ,medicine.disease ,Targeted therapy ,Myristoylation - Abstract
Human N-myristoyltransferases (NMTs) catalyze N-terminal protein myristoylation, a modification regulating membrane trafficking and interactions of >100 proteins. NMT is a promising target in cancer, but a mechanistic rationale for targeted therapy remains poorly defined. Here, large-scale cancer cell line screens against a panel of NMT inhibitors (NMTi) were combined with systems-level analyses to reveal that NMTi is synthetic lethal with deregulated MYC. Synthetic lethality is mediated by post-transcriptional failure in mitochondrial respiratory complex I protein synthesis concurrent with loss of myristoylation and degradation of complex I assembly factor NDUFAF4, followed by mitochondrial dysfunction specifically in MYC-deregulated cancer cells. NMTi eliminated MYC-deregulated tumors in vivo without overt toxicity, providing a new paradigm in which targeting a constitutive co-translational protein modification is synthetically lethal in MYC-deregulated cancers.One-sentence summaryN-myristoyltransferase inhibition leads to post-transcriptional complex I failure and cell death in MYC-deregulated cancers
- Published
- 2021
- Full Text
- View/download PDF